- Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromesFarhan Imran
Department of Medicine, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621, USA
Expert Rev Pharmacoecon Outcomes Res 9:297-304. 2009..Deferasirox may also have potential as an important supplement and even an alternative to phlebotomies in nontransfusional, genetic iron overload disorders, such as hereditary hemochromatosis...
- A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosisPradyumna Phatak
Rochester General Hospital, Rochester, NY, USA
Hepatology 52:1671-779. 2010..After receiving deferasirox for 48 weeks, median serum ferritin levels decreased by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively. In all cohorts, median serum ferritin decreased to < 250 ng/mL...